0.01 | 0.22%
| Price and Volume | |
|---|---|
| Recent Price | 4.61 |
| 52 Week High | 11.68 |
| 52 Week Low | 3.94 |
| Avg. Daily Vol. (Mil) | 1.70 |
| Beta (3 year) | 2.82 |
| Share Related Items | |
| Mkt Cap (Mil) | 684.48 |
| Shares Out (Mil) | 148.48 |
| Float (Mil) | 92.50 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.80 |
| Current Ratio | 2.90 |
| LT Debt/ Equity | 1.27 |
| Total Debt / Equity | 1.38 |
| Valuation Ratios | |
| Price Earnings | 7.70 |
| Price/Sales | 2.51 |
| Price/Book | 5.17 |
| Price/Cash Flow | 8.20 |
| Per Share Data | |
| Earnings | 0.60 |
| Sales | 1.83 |
| Book Value | 0.89 |
| Cash Flow | 0.56 |
| Business Summary | |
|---|---|
| Exelixis, Inc. is committed to developing innovative therapies for cancer and other serious diseases. | |
| General Information | |
| 210 East Grand Avenue
South San Francisc, CA 94080 |
|
| www.exelixis.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 200 | |
| CEO: Dr. Michael M. Morrissey | |
| Short Interest | |
| Current Month (Mil) | 21.17 |
| Previous Month (Mil) | 19.87 |
| Short Interest Ratio (Days) | 12.60 |
| Management Effectiveness | |
| Return on Equity | 58.20 |
| Return on Assets | 18.70 |
| Return on Investments | 25.60 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | 34.80 |
| Profit Margin | 28.30 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet